Alendronate and Vitamin D3 Combination Therapy

Introduction to Combination Therapy

• The National Osteoporosis Foundation recommends supplemental calcium (1200 mg/day) and vitamin D3 (800-1000 IU/day) for all men >50 years of age receiving bisphosphonate therapy, such as alendronate, to optimize bone health 2

Patient Population Considerations

• For cholestatic liver disease patients on bisphosphonates, calcium (1000-1200 mg/day) and vitamin D (400-800 IU/day) supplementation should be considered to prevent hypocalcemia and ensure adequate mineral metabolism 3
• ASCO guidelines recommend that bone-modifying agents like alendronate should be given alongside vitamin D supplementation and adequate calcium intake to minimize the risk of hypocalcemia and optimize therapeutic outcomes 4

Correction of Vitamin D Deficiency

• Both IV bisphosphonates and oral bisphosphonates require vitamin D deficiency correction before initiation to avoid hypocalcemia, emphasizing the importance of adequate vitamin D levels in patients receiving bisphosphonate therapy 1